In Part two of this two-part series, we look at what companies should do to make the exit from stealth mode an effective exchange with the outside world — how to identify and reach investors, influencers, and stakeholders in a company’s pursuit of new treatments for diseases, from rare conditions to widespread medical challenges, some at the scale of public health.

Terry Coelho, CFO, works as a team member, not just a finance manager, at BioDelivery Sciences.

NervGen Pharma is going beyond preclinicals to human trials for a drug that could repair and regrow neurons.

Five CEOs discuss their experiences with stealth mode transitions. They address when and how a company should turn away from that introspective state and show itself to the world.

Our company to watch this month is IM Therapeutics, which focuses on developing small molecule therapies for Type 1 diabetes, celiac disease, and other autoimmune conditions.

From the outside, it may look as if Biophytis took a sharp turn from its focus on aging to address Covid. But look again.

Our company to watch this month, Lyra Therapeutics, is focused on controlling chronic ENT conditions with precise drug elution and long action.

At 180 Life Sciences, veterans of the old-pharma world are building a small bio enterprise focused evenly on scientific and market opportunities in the inflammation space.

Carisma Therapeutics is a private company developing CAR-M (chimeric antigen receptor macrophage) as an alternative to CAR-T (CAR-T cell) and potential treatment for solid tumors rather than just liquid cancers.

Long before the Warp Speed race, vaccines were a global business more characterized by collaboration than competition. In concert with its national regulator, Health Canada, IMV, Inc. could make world history with its approach to COVID vaccination.

PhaseBio is a small, public company aiming to enter a large-market therapeutic area: cardiovascular.

Companies To Watch: Akero Therapeutics - Test-proofing a new metabolism drug to beat the liver disease, NASH

Dicerna shows how the multitude of “co-opportunities” of COVID in the RNA space has further encouraged companies to exploit the unique attributes of those approaches well beyond dealing with the immediate viral threat.

Just as the COVID pandemic hit, Timber Pharma was planning on going public. But that wasn’t the only challenge the company faced in the months ahead.